CYBN:CC News and Press, CYBIN INC. From 07/24/23

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that its phase 2 trial evaluating CYB003, an investigational pro...

Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder Canada NewsWire - Cohort 5 completed with no safety or tolerability issues, Final cohort 6 is recruiting with dosing expected to commence shortly - - Phase 2 efficacy data for C...

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, commends Kernel, a leade...

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on the release of study findings. Cybin sponsored the study, which was conduc...

Kernel, a leader in non-invasive neuroimaging, announces the publication of their study " Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS ," in the journal Scientific Reports from the Nature Portfolio of Journals. The study, sponsored...

Cybin (NEO: CYBN) (NYSE American: CYBN ), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is developing a streamlined, scalable version of its EMBARK Training Program, known as EMB...

- EMBARK for Clinical Trials (“EMBARK CT ”) being developed as a scalable model of psychedelic facilitation training to support future pivotal studies - - American Medical Association (“AMA”)’s new CPT codes will support potential reimbursement of in...

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has appointed Aaron Bartlone as its chief operating officer; Bartlone has been the COO for...

- Cybin’s Chief Medical Officer Amir Inamdar to participate in a fireside chat on July 6, 2023 - Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutioniz...

This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplement dated August 8, 2022 and prospectus supplement dated May 30, 2023 to its short form base shelf prospectus dated July 5, 2021 Cybin Inc. (NEO:CYBN) (NYSE A...